COST-EFFECTIVENESS OF BIOSIMILAR ETANERCEPT IN CLINICAL PRACTICE USE

Ruiz García S, Ramírez Herraiz E, Calvo García A, Martínez Nieto C, Morell Baladrón A

Pharmacy Department. La Princesa University Hospital. Madrid, Spain.

OBJETIVES

- To evaluate biosimilar etanercept effectiveness in patients with rheumatoid arthritis (RA).
- To calculate the saving due to use biosimilar versus original drug.


METHODS

- Retrospective observational study (January 2017 August 2018).
- Patients with RA who initied treatment with a biosimilar etanercept.
- Collected data: drug, age, sex, dose, schedule, concomitant Disease-Modifying Antirheumatic Drugs (DMARD), previous biological drugs, treatment
 length and baseline and final Disease Activity Score (DAS28).
- Data sources: electronic medical records and outpatients electronic prescription. Considered costs were hospital average prices.

RESULTS

 \rightarrow 16 patients with documented DAS28.

	Global	Benepali®	Erelzi®
Patients (%)	_	50	50
Sex (% female)	81,3	75	87,5
Median age (years)	61	61	60,5
Median treatment duration (days)	186	253,5	143,5
Concomitant DMARD (%)	100	100	100



Previous lines	DAS28 difference	p value
Naive	1,453	0,006
1	0,740	0,287
2	0,350	0,496

Biosimilar drug	DAS28 difference	p value
Benepali®	1,443	0,014
Erelzi®	0,645	0,068

Saving vs original drug: 27,47% (34,93% Benepali®, 20% Erelzi®)



DISCUSSION

- Effectiveness results were similar to data described in bibliography for original drug.
- Both biosimilar drugs show a decrease of DAS28. Erelzi® was statistically not significant possibly because of its lower treatment length in this study.
- DAS28 difference was statistically significant in naive patients; however, it wasn't in those who received more than two lines.

CONCLUSIONS

- Biosimilar drugs effectiveness was similar to original drug. Decrease in DAS28 was better in naive patients.
- The use of biosimilar drugs instead of original drug entails an important saving.
- These results require confirmation in studies of long-term persistence.







